Diabetes Drugs Market Size, Industry Trends and Forecast to 2027Posted by shriya on June 17th, 2021 Diabetes Drug Market Research Report, Type of Diabetes (Type-1 And Type-2), By Administration (Oral, Intravenous, Other), By Drug Class (Insulin, Sensitizers, SGLT-2 Inhibitors, Alpha-Glucosidase Inhibitors), By End Users (Hospital & Clinics, Ambulatory Clinics) - Global Forecast to 2027 The global diabetes drug market is expected to expand in size and grow at a CAGR of 6.38% over the forecast period of 2017-2023, claims Market Research Future (MRFR) in a minutely analyzed research report. The diabetes drug market has been growing continuously on account of steadily growing number of cases and prevalence of diabetes over the past few years. Sedentary lifestyle along with consumption of high-calorie food accentuates the prevalence of diabetes. Owing to the high incidence and progressive nature of the disease, there are substantial high unmet medical needs which drives the diabetes drug market. Regional analysis The key markets of the global diabetes drug market include the Americas, Europe, Asia Pacific and the Middle East & Africa. The Americas is leading the global market for diabetes drug owing to a large diabetic patient population. High expenditure on healthcare coupled with increasing awareness regarding the treatment options available also boosts the growth of the market. Competitive Landscape The notable players of the market include Eli Lilly (US), Abbott (US), Biocon (US), Sanofi (France), Merck & Co. (US), Daiichi Sankyo (Japan), Akros Pharma (US), Adocia (France), Takeda (Japan), Novo Nordisk (Denmark), AstraZeneca (UK), Sunpharma (India), Novartis (Switzerland), Pfizer (US), Boehringer Ingelheim (Germany), Amgen (US), and Peptron (South Korea). Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/diabetes-drug-market-1160 Contact: Akash Anand Market Research Future +1 646 845 9312 Like it? Share it! More by this author |